Bill Harriman

Bill Harriman has over 25 years of work experience in the biotechnology and pharmaceutical industry. Bill is currently the SVP Antibody Discovery at OmniAb, Inc. since November 2022. Prior to that, from November 2020 to November 2022, they held the same role at Ligand Pharmaceuticals. From 2017 to 2020, they served as the Vice President, Antibody Discovery at Ligand Pharmaceuticals.

Before joining Ligand Pharmaceuticals, Bill Harriman was the CSO & co-Founder of Crystal Bioscience from October 2008 to October 2017. During their time there, they managed the development of Crystal's core antibody discovery platform and created a work environment that fostered exceptional scientific achievements. Bill also provided a vision for the company's assets and value creation.

From 2002 to 2008, they worked as the Director of Molecular Biology at Trellis Bioscience. Prior to that, they served as a Senior Scientist at Roche Diagnostics from 1996 to 2000. Bill began their career as a Postdoc at Abgenix in 1995.

Overall, Bill Harriman has a strong background in antibody discovery and has held several leadership positions throughout their career.

Bill Harriman has a strong educational background with multiple degrees. In 1982, they attended the University of California, Berkeley and completed their Bachelor of Arts degree in Immunogenetics in 1987. Following this, they pursued further education in the field of Immunology at the University of California, San Francisco, where they obtained their PhD degree from 1988 to 1995. Later, from 1998 to 2000, Bill enrolled at the University of California, Berkeley, Haas School of Business, where they earned an MBA degree in the Management of Technology.